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Abstract
Background. Grey matter (GM) reduction is a consistent observation in established late
stages of schizophrenia, but patients in the untreated early stages of illness display an increase
as well as a decrease in GM distribution relative to healthy controls (HC). The relative excess
of GM may indicate putative compensatory responses, though to date its relevance is unclear.
Methods. 343 ﬁrst-episode treatment-naïve patients with schizophrenia (FES) and 342 HC
were recruited. Multivariate source-based morphometry was performed to identify covarying
‘networks’ of grey matter concentration (GMC). Neurocognitive scores using the Cambridge
Neuropsychological Test Automated Battery (CANTAB) and symptom burden using the
Positive and Negative Symptoms Scale (PANSS) were obtained. Bivariate linear relationships
between GMC and cognition/symptoms were studied.
Results. Compared to healthy subjects, FES had prominently lower GMC in two components;
the first consists of the anterior insula, inferior frontal gyrus, anterior cingulate and the second
component with the superior temporal gyrus, precuneus, inferior/superior parietal lobule,
cuneus, and lingual gyrus. Higher GMC was seen in adjacent areas of the middle and superior
temporal gyrus, middle frontal gyrus, inferior parietal cortex and putamen. Greater GMC of
this component was associated with lower duration of untreated psychosis, less severe positive
symptoms and better performance on cognitive tests.
Conclusions. In untreated stages of schizophrenia, both a distributed lower and higher GMC
is observable. While the higher GMC is relatively modest, it occurs across frontoparietal, temporal and subcortical regions in association with reduced illness burden suggesting a compensatory role for higher GMC in the early stages of schizophrenia.

Introduction

© The Author(s), 2022. Published by
Cambridge University Press. This is an Open
Access article, distributed under the terms of
the Creative Commons Attribution licence
(http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted re-use, distribution
and reproduction, provided the original article
is properly cited.

Progressive loss of grey matter (GM) tissue is one of the presumed pathophysiological
processes targeted by the paradigm of ‘early intervention’ in psychosis (Lieberman, Small, &
Girgis, 2019; Palaniyappan, 2021). Several longitudinal observations report a progressive
loss of GM in patients with schizophrenia, occurring at a rate greater than expected from
healthy individuals (Vita, De Peri, Deste, & Sacchetti, 2012). This lower GM appears to be spatially constrained to key cortical regions (frontoinsular and temporal cortex), and temporally
limited to the period immediately after the first episode (Palaniyappan, 2017). GM reduction
also appears to be more pronounced in patients with severe cognitive impairment at the time
of the first presentation, though its relationship with symptom burden at presentation is still
unclear (Takahashi & Suzuki, 2018).
Recently emerging evidence indicates that a subtle but progressive increase in the GM may
occur alongside a progressive loss in patients with schizophrenia. This gain appears to be spatially more diffuse and not identifiable by conventional mass univariate analyses. Nevertheless,
the relative increase becomes apparent in covariance analyses (Guo, Palaniyappan, Liddle, &
Feng, 2016; Kasparek et al., 2010; Palaniyappan et al., 2015). Lv et al. recently used normative
modelling and reported that while 79% of patients with schizophrenia show infra-normal
deviations in brain structure (i.e. <5th percentile value of age- and sex-matched healthy individuals), 46% show supra-normal deviations (i.e. >95th percentile value) for at least one brain
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region (Lv et al., 2021). Areas of higher GM were less regionally
concentrated than lower GM reduction. Mancuso and colleagues
used a meta-analytical network mapping approach and concluded
that whenever GM reduction occurs in one brain region, concurrent GM increase occurs in other brain regions in schizophrenia
(Mancuso et al., 2020). In addition, meta-analytic evidence of
cross-sectional studies indicates that while some regional GM
changes persist or expand in chronic schizophrenia, others ameliorate, ‘closing the gap’ with healthy controls (HC) (Liloia et al.,
2021). Taken together, these findings support a process of
reorganisation characterised by concurrent GM loss as well as
gain in schizophrenia. At present, it is unclear if the GM increase
occurs even before the onset of treatment (thus an inherent process independent of medication exposure), and if such increases
are indeed associated with a favourable clinical profile [thus a
compensatory process (Palaniyappan, 2019)].
In this work, we investigate the relative increases and decreases
in GM in the largest ever-reported sample of ﬁrst-episode
neuroleptic-naïve patients with schizophreniform psychosis and
schizophrenia (NN-FES, n = 343) and matched healthy subjects
(n = 342). As patients with a more severe illness often receive a
higher antipsychotic dose, which is independently associated
with GM reduction (Voineskos et al., 2020) as well as an increase
(Stip et al., 2009), the recruitment of a challenging sample of fully
NN-FES is crucial to study the possibility of a compensatory
amelioration. Besides recruiting the sample of NN-FES, we also
employ a covariance analysis that utilises a multivariate approach
as opposed to the mass univariate approaches of voxel-based
morphometry (VBM). The mass univariate approach of VBM
search fails to consider the relationship among brain regions in
structural changes introduced by maturational or neuroplastic
processes, and the intrinsic connectivity (‘common fate’).
Source-based morphometry (SBM) is a multivariate extension
of VBM with independent component analysis identifying naturally grouping, maximally independent sources; the identified
‘source networks’ provide information about localisation of GM
changes and their variation among individuals (Kasparek et al.,
2010; Xu, Groth, Pearlson, Schretlen, & Calhoun, 2009). This
approach also increases the sensitivity of detecting anatomical
changes by compartmentalising noise and scanner effects, and
allows distributed brain regions sharing ‘common fate’ to be studied as single units (Gupta et al., 2015). As a result, the ability to
detect a concurrent GM increase that accompanies a GM decrease
is improved when employing SBM.
In the present study, we hypothesise that a relative increase in
GM, compared to healthy individuals, occurs alongside more
widespread GM reduction in the early stages of schizophrenia.
We expect this relative increase to occur in those with more
favourable cognitive and symptom profiles even before the
onset of treatment. We also investigate the effects of the duration
of untreated illness, symptom burden and cognitive function
across multiple domains to address the question of compensatory
cortical reorganisation characterised by concurrent GM deficits
and excesses in schizophrenia.

Material and methods
Subjects
343 ﬁrst-episode neuroleptic-naïve patients with schizophreniform psychosis and schizophrenia (NN-FES) (age from 16 to 45
years) from the Mental Health Center in West China Hospital
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and 342 HC (age from 16 to 45 years) were enrolled in the present
study. Patients were interviewed and assessed using the Structured
Clinical Interview for the DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, fourth edition) (SCID-I/P) (First,
Spitzer, & Williams, 1997), and fulfilled diagnostic criteria for
schizophrenia or schizophreniform psychosis in the DSM-IV.
Subjects with evidence of organic brain disorders, alcohol or operationally defined ‘drug abuse’, or any other severe physical illness
such as brain tumour or epilepsy, coronary heart disease, hyperthyroidism, serious kidney or liver disease and pulmonary infection were excluded. The ‘drug abuse’ definition was based on the
drug list in SCID-I including sedative, cannabis, stimulant, opioid,
cocaine, hallucinogen, phencyclidine and others (e.g. steroid medicines, diet pills).
342 HC were recruited from the local area by poster advertisements. All controls were screened for the lifetime absence of
psychiatric illnesses by using the SCID non-patient version
(SCID-I/NP) (First, SR, & Williams, 1996). In addition, control
subjects were interviewed to ascertain that there was no psychiatric illness among their first-degree relatives.
All participants were Han Chinese and right-handed. The
handedness of participants was assessed with Annett
Handedness Scale (Annett, 1970). This study was carried out in
accordance with the Declaration of Helsinki and was approved
by the Institutional Review Board of West China Hospital,
Sichuan University (2005NO.34 & 2013NO.89). After a complete
description of the study to the subjects, written informed consent
was obtained from the HC and patients and their guardians when
appropriate.
The severity of symptoms was evaluated using the 30-item
Positive and Negative Symptoms Scale (PANSS) (Kay, Flszbein,
& Opfer, 1987). PANSS scores were available for 295 of 343
NN-FES subjects. Neurocognition was assessed using the
Cambridge Neuropsychological Test Automated Battery
(CANTAB) including six computerised tasks [Rapid Visual
Information Processing (RVP), Pattern Recognition Memory
(PRM), Delayed Matching to Sample (DMS), Spatial Working
Memory (SWM), Intra-Extra Dimensional Set Shift (IED),
Stockings of Cambridge (SOC)] from the CANTAB-eclipse running on a personal computer with a high-resolution touchscreen.
For more detailed descriptions of these tests see the CANTAB®
website (www.cambridgecognition.com). 210 of 343 NN-FES
and 253 of 342 HC had CANTAB data available. A total of 214
NN-FES and 292 HC were assessed using the short version of
the seven-subtest (information, arithmetic, digital symbol, digital
span test, block design, picture completion, and similarities)
Chinese Revised Version of the Wechsler Adult Intelligence
Scale (WAIS-RC) (Gong, 1992). CANTAB and PANSS were
administered within two days of the scan in all cases.
Magnetic resonance imaging (MRI) data acquisition
Patients were scanned after written informed consent
was obtained, but before treatment initiation; in all cases, this
was on the same day of initial assessment, along with other
laboratory assessments required for routine clinical care.
Patients were not included in the study if any exposure to antipsychotics took place before the scanning. 206 patients and 170 HC
were scanned on a Signa 3.0-T MR scanner [General Electric
(GE), Medical Systems, USA] using an eight-channel
phased-array head coil in the Department of Radiology at West
China Hospital. The scan parameters are listed in the
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Supplementary Methods. 137 patients and 172 HC were scanned
on a 3.0 T MR scanner (Philips Achieva, Amsterdam, the
Netherlands) using an eight-channel phased-array head coil in
the department of Radiology at West China Hospital Tibet
People’s Government in Chengdu Office Branch. The data from
the 2 scanners (datasets 1 and 2 respectively) were combined
for aggregated analysis; see online supplementary materials for
scanner-related variations.
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spatial component is predominantly positive, with the loading
coefficients greater in HC than NN-FES, we infer that grey matter
concentration (GMC) is greater in HC for the spatial component
under consideration. If a spatial component is predominantly
negative, with the loading coefficients being greater in HC than
NN-FES, GMC is lower in HC compared to NN-FES for the spatial component under consideration.
We also conducted a VBM analysis comparing the 2 groups
(details in the online Supplement).

T1 image preprocessing and source-based morphometry (SBM)
To improve the registration of the MRI images, T1 Images were
processed using Diffeomorphic Anatomical Registration
Through Exponentiated Lie algebra (DARTEL) toolbox in
Statistical Parametric Mapping (SPM) 8, and followed the standard approach of Ashburner (2007). The details of VBM preprocessing is shown in the Supplementary Methods. Finally, these
unmodulated grey-matter images were smoothed with an isotropic Gaussian kernel of 6-mm full-width, half-maximum to
be used in the next step analysis.
The SBM module of the GIFT Toolbox (http://mialab.mrn.org/
software/gift/) was used to perform the independent component
analysis decompositions on the aggregated dataset consisting of
343 NN-FES and 342 HC from 2 scanners (Xu et al., 2009).
The number of components was set to 30 as previous studies suggested (Gupta et al., 2015; Xu et al., 2009). We employed a bootstrapping approach [ICASSO: (http://research.ics.aalto.fi/ica/
icasso/) (Himberg, Hyvarinen, & Esposito, 2004)] with 20 iterations to resample the available data while retaining the structure
within the data; this simulated a random sampling process,
providing estimates of the statistical reliability of components,
and allowing the unstable components to be discarded. The
subjects-by-voxels matrix was decomposed into a mixing matrix
(subjects-by-components) representing loading parameters that
quantify the contribution of each subject to the group for a
given component and source matrix (components-by-voxels)
representing the spatially independent ‘sub-systems’ defined on
the basis of morphometric covariance within the group as
in our previous study (Palaniyappan et al., 2015). Artefact components were identified visually and not included in subsequent analyses. To confirm the robustness of these findings across the
scanners, we also performed separate SBM decompositions for
the 2 datasets.
To visualise the spatial components, the source matrix was
recomposed to statistical maps in 3-dimensional MNI space
with coefficients expressed in standard deviation units (z-maps).
These source maps were scaled to unit standard deviation (SBM
Z map) and thresholded at a value of |Z| > 3:0. The anatomical
descriptions of these maps were obtained using Talairach coordinates utility in the GIFT toolbox.
The GM intensity in each voxel in each subject (after removal
of the group mean) is the sum of 30 product values obtained from
multiplying the voxel loading for each component with its coefficient for that subject. The sign of the loading coefficients of a
component in a subject does not directly provide the direction
of change in absolute GM intensity in a region (Gupta et al.,
2015). As a result, interpretation of the loading coefficients of
the spatial ICA GM maps needs some care. A larger loading
coefficient for an individual or group indicates that the spatial
pattern is more strongly weighted in the data for that individual
or group, but the interpretation of the loading coefficient difference depends upon the spatial image of the component. If a
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Statistical analysis
Demographic and clinical characteristics
Independent two-sample t tests (continuous variables) or χ2 tests
(categorical variables) were used to evaluate differences in demographic and clinical characteristics between NN-FES and HC. All
statistical tests were carried out using SPSS, Version 18.0. (IBM,
Armonk, New York).
The differences in loading coefficients between NN-FES and HC
participants
A multivariate analysis of covariance (MANCOVA) model was
used with SBM loading coefficients as dependent variables, diagnosis as a factor, and scanner, age, gender, years of education and
intracranial volume as covariates in SPSS 18.0. A threshold of p <
0.05 after correcting for multiple testing using the false discovery
rate (FDR) method was used to infer statistical significance for
group comparisons. SBM analysis was repeated on the two
scanner-specific datasets separately to confirm the results from
the combined analysis (See online Supplement section 4).
Principal component analysis for neurocognition from CANTAB
Principal component analysis (PCA) was used for dimensionality
reduction across the 16 scores from 6 CANTAB subtests. The
latent variables from the PCA were assumed to reflect underlying
cognitive dimensions. For this PCA, a parallel analysis (PA)
helped determine the most appropriate number of components
to be retained. As the components were expected to be correlated,
we employed a varimax rotation (Further details in the
Supplement).
Correlates of clinical and neurocognitive variables with SBM
loading coefficients
To exclude the effects of scanner, age, sex, and years of education
on loading parameters of components, multiple regression analyses were performed on each SBM component as dependent variables, and scanner, age, gender, educational years and intracranial
volume as independent variables, in the HC and NN-FES separately. Standard residual scores of each component from these
regressions were then substituted for the raw values in the correlation analyses with clinical and neurocognitive variables.
As the duration of the untreated psychosis (DUP) showed a
skewed distribution, Spearman’s test was used to assess the relationship between DUP and the SBM components showing
group difference. Pearson’s test was used to evaluate the relationship between the SBM components and positive, negative,
and disorganisation factor scores from PANSS (van der Gaag
et al., 2006) as well as age in the patient group for the identified
SBM components (We report multiple regression analyses at a
whole-brain level in the supplement). Additionally, when examining the correlation between SBM components and 4 cognitive factors from PCA of CANTAB scores, we used partial correlation

4

adjusting for full-scale IQ. We also examined the relationship
between components showing lower and higher GM in patients
using Pearson’s test.
Correlations were deemed statistically significant based on an
FDR-corrected p < 0.05 threshold.
Results
Demographic and clinical characteristics
Demographic, clinical, and neurocognitive features of the sample
are presented in Table 1. The two groups were well matched for
age and gender. The NN-FES had lower number of years
of education and intelligence quotient (IQ) scores than HC, as
expected (Also see online Supplementary Tables S1 and S2).
Patients scanned with the GE system were more symptomatic
than the other group scanned with the Phillips scanner, but
there were no differences in age, DUP or neurocognition (see
online Supplementary materials).
SBM results
The tissue maps of GMC were decomposed into 30 SBM components. Eight components were suggestive of obvious artefacts, i.e.
having spatial patterns primarily around the edges of the brain, in
white matter regions or CSF and these were discarded (online
Supplementary Fig. S7). From the remaining components, we
observed four spatial patterns showing a significant effect of diagnosis. These four components and their spatial patterns are
depicted in Fig. 1 and Table 2 with brain regions having volumes
greater than 1 cm3, labelled in the order of decreasing effect sizes.
Components 4 and 24 included areas where GMC values were
greater in HC than NN-FES. Component 4 included insula, inferior frontal gyrus, anterior cingulate and superior temporal gyrus.
Component 24 included precuneus, inferior/superior parietal
lobule, cuneus, and lingual gyrus. In contrast, component 13
(including cerebellar tonsil and inferior semi-lunar lobule) and
component 26 (including middle and superior temporal gyrus,
middle frontal gyrus and putamen) had areas with higher GMC
in NN-FES than HC (Fig. 2). The brain labels in Table 2 were
obtained from the Talairach Daemon (http://www.talairach.org/
daemon.html) based on the transformed locations of the largest
clusters in the component maps. All four components had similar
diagnostic differences when scanner-specific subsets of data were
analysed, but a component with spatial similarity to component
13 was not recovered independently from the Philips scanner
(see online Supplementary materials for scanner effects).
PCA of CANTAB scores
Four distinctly interpretable components explaining 77.15% of
the total variance emerged from 16 variables in 6 CANTAB subtests with the PCA. PC1 included five CANTAB subtest variables
(RVP, SWM, DMS, PRM and SOC) representing sustained attention, memory and planning ability (Higher score is better for the
neurocognitive ability of PC1) (factor loadings 0.53–0.90); PC2
included the CANTAB subtest variable IED reflecting cognitive
set-shifting (lower score of PC 2, the better cognitive set-shifting
ability) (factor loadings 0.95–0.97); PC3 was comprised of RVP
Probability of false alarm (RVP-PFA) and RVP B′′ (measure the
tendency to respond regardless of whether the target sequence
is present) (factor loadings 0.93) (higher is better); PC4 was comprised of DMS per cent correct, DMS per cent correct in n ms
delay and Pattern Recognition Memory per cent correct in
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immediate test (factor loadings 0.48–0.82) (Higher score, better
immediate memory). (See online Supplementary Table S6 and
Fig. S3). NN-FES showed impaired neurocognition in all four
components when compared to HC (Table 3).
Clinical and cognitive correlates of GMC
Component 26 (with contributions from middle frontal, superior
temporal gyrus and putamen) significantly related to the duration
of psychosis (r = 0.152, FDR-corrected for clinical features p =
0.04), positive symptoms (r = 0.178, FDR-corrected for clinical
features p = 0.04) and to neurocognitive factor 2 (adjusted for
IQ) (r = 0.220, FDR-corrected for cognitive components p =
0.056) (Table 4). This indicated that shorter DUP, less severe positive symptoms, and better performance on IED are associated
with greater GMC in the regions included in component 26 –
middle frontal, superior temporal gyrus and putamen. In addition, variance in age is significantly related to the variance in
loading coefficients of component 26 (r = 0.218, FDR-corrected
p = 9.2 × 10−5) and component 4 (r = −0.246, FDR-corrected p
= 1.6 × 10−5) among patients. The observed direction of this relationship indicated that younger patients had higher GMC for
both components, but the R 2 of these models were small (4.7–
6.04%) (online Supplementary Fig. S4). No other significant correlation was found between GM spatial components, clinical or
neurocognitive variables.
Correlation between components showing lower and higher GMC
in patients
In the patient group, the loading on component 4 was significantly related to component 24 (r = −0.441, FDR-corrected p <
0.0001) and component 13 (r = 0.200, FDR-corrected p <
0.0001) and component 26 (r = −0.219, FDR-corrected p =
0.0001). The loading on component 24 was significantly related
to component 13 (r = −0.208, FDR-corrected p < 0.0002). As
component 4 was a predominantly positively loading spatial component while components 24, 13 and 26 were predominantly
negative components, these correlations indicated that patients
with lower GMC in one component (4 or 24) are likely to also
have higher GMC in either component 13 (with lower GMC in
component 4 or 24) or component 26 (with lower GMC in either
component 4). No significant correlation was found between
component 24 and component 26 as well as between component
13 and component 26 (online Supplementary Table S7), indicating that patients did not share the distribution of relative higher in
GMC; while some patients had predominant higher GMC of
component 13, others had a predominant higher GMC in component 26.
VBM results
Compared with HC, patients with NN-FES had lower GMC in the
bilateral cingulate gyrus, insular, right superior temporal gyrus,
medial orbital frontal, rectus, caudate, precentral gyrus and lingual
gyrus at FWE-corrected p < 0.05 and an extent threshold of 50 voxels, with no significant results for higher GMC in NN-FES group at
this statistical threshold (online Supplementary Fig. S5a). However,
when we used a more liberal threshold, higher GMC in the NN-FES
group were found in caudate, cerebellum and a temporal pole at p <
0.001 at voxel level with FWE-corrected p < 0.05 at the cluster level,
overlapping, and thus validating the interpreted direction of greater
GMC in patients from the SBM analysis (online Supplementary
Fig. S5b).
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Table 1. Demographics and clinical information of aggregate data
NN-FES (n = 343)

Control (n = 342)

df

T/χ2 value

p value

Age (years)

23.76 (7.10)

24.33 (5.68)

683

−1.16

0.25

Years of education

11.96 (2.99)

14.74 (2.30)

683

−12.16

0.00

1

2.98

0.09

504

−16.45

0.00

Gender (M/F)
Age of onset
DUP (months)

170/173

147/195

22.83 (7.14)
4 (1; 15)a

Positive

26.30 (6.20)

Negative

23.60 (9.81)

Disorganisation

32.17 (7.66)

IQ

99.65 (13.63)

118.12 (11.56)

NN-FES, ﬁrst-episode neuroleptic-naïve patients with schizophreniform psychosis and schizophrenia; DUP, duration of untreated psychosis; M/F, male/female; IQ, intelligence quotient.
a
Median (quarter; three quarters).

Discussion
Using multivariate SBM in a sample of treatment-naïve
first-episode patients with schizophrenia, we report three major
findings. Firstly, we found both a prominently lower grey matter
concentration in frontoinsular, temporal and parietal regions, and
a higher GMC in a distributed cortical/subcortical component
(middle and superior temporal gyrus, middle frontal gyrus and
putamen), and cerebellum (tonsil and inferior semi-lunar lobule).
Second, the higher GM in the cortico/subcortical component was
seen in patients with shorter DUP and was associated with less
severe positive symptoms and better performance on set-shifting
ability, suggesting an adaptive advantage for patients with relative
GM increase in these regions. Third, there was a significant relationship between the spatial components showing higher and
lower GMC, supporting a coordinated reorganisation process.
Taken together, these findings delineate a distributed pattern of
GM changes in schizophrenia before any antipsychotic exposure.
When undertaking a VBM analysis, the subtle effect of higher
GMC in the patient group was not detectable at FWE-corrected
p < 0.05 for voxel level, but this became obvious at a lower threshold at p < 0.001 uncorrected at voxel level (online Supplementary
Fig. S5). This supports our notion that in order to detect GM
increases in schizophrenia, mass univariate approaches that
depend on spatially contiguous clusters are less sensitive than
approaches like SBM that leverage more distributed changes.
Though the diagnostic effect of the cerebellar component did
not independently replicate in the smaller of the 2 datasets, our
observation of higher GM in NN-FES involving the cerebellum,
middle and superior temporal gyrus, middle frontal gyrus, inferior parietal lobule and putamen is consistent with several studies
with large sample size (>100 subjects) (Ren et al., 2013; Xiao et al.,
2015) and the only previous study to use SBM in first-episode
schizophrenia (Kasparek et al., 2010). In particular, increased
thickness in overlapping cortical regions was reported in 128
patients with NN-FES (Xiao et al., 2015) and in brainstem and
cerebellum in chronic and medicated patients with schizophrenia
in a mega-analysis of 784 patients (Gupta et al., 2015). A recent
meta-analysis has established a relative increase in GM in patients
with chronic compared to recent-onset schizophrenia, affecting
an estimated probability affecting 672 mm3 of the GM despite a
more extensive 1464 mm3 of the relative decrease in the chronic
samples (Liloia et al., 2021). While antipsychotics have been
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implicated in tissue loss (Arnone et al., 2009; Vita, De Peri,
Deste, Barlati, & Sacchetti, 2015), their role in a relative increase
in the GM has been less well established (Feng et al., 2020; Yue
et al., 2016; Zhang et al., 2018). In a unique cohort with a very
long duration of untreated schizophrenia (20 years), Liu and colleagues observed a relative increase in GM compared to durationmatched but medicated patients with chronic schizophrenia (Liu
et al., 2020). More recently, Chopra et al. demonstrated
antipsychotic-induced subcortical volume increase as a correlate
of treatment response in first-episode schizophrenia (Chopra
et al., 2021). Our report of a relatively higher GM in NN-FES
adds to these findings, and clarifies that higher GM is not a latestage phenomenon, as speculated previously (Guo et al., 2016),
but occurs very early in the illness, even before antipsychotic
exposure.
The most prominent lower GMC in patients with psychosis
was located on the insula, inferior frontal gyrus, anterior cingulate
and superior temporal gyrus, which were also observed in our
VBM analysis. The two lower GMC components were distributed
across four functional networks; anterior insular cortex and anterior cingulate comprising the mid-cinguloinsular salience network
(Seeley et al., 2007), superior temporal gyrus comprising the primary auditory network, precuneus and inferior parietal lobule
constituting the posterior aspect of the pericentral default mode
network, and cuneus and lingual gyrus being part of the visual
network (Uddin, Yeo, & Spreng, 2019). This result is highly consistent with the findings of previous meta-analysis studies (Chan,
Di, McAlonan, & Gong, 2011; Glahn et al., 2008; Honea, Crow,
Passingham, & Mackay, 2005) and a recent international megaanalysis study on antipsychotic treated patients at a clinically
stable state (Gupta et al., 2015). Moreover, in a prior
meta-analytical study, we observed that the GM deficits affecting
insula, STG, and ACC are seen in association with expression of
the schizophrenia phenotype, but not in high-risk relatives (HRR)
of patients with schizophrenia (Palaniyappan, Balain, & Liddle,
2012). Taken together, these findings suggest that lower GM of
these key regions exist at a drug-naive first episode stage of the illness and continue to be present despite antipsychotic treatment in
later stages.
We did not observe a relationship between components with
lower GM and cognition/symptom scores. This suggests that the
relative reduction of GM at the time of onset is unlikely to be a
major determinant of the severity of illness at presentation,
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Fig. 1. Spatial maps of the four components showing (NN-FES v. HC) group effect. All are thresholded at |z| > 3 and superimposed onto a standard brain template
provided by MRICron. The colour bar indicates the colour mapping for the normalised component weights. HC > NN-FES: component 4, 24; NN-FES > HC: component 13, 26. SBM, source-based morphometry; HC, healthy control; NN-FES, ﬁrst-episode neuroleptic-naïve patients with schizophreniform psychosis and
schizophrenia.

though this may relate to illness persistence or non-response
(Li et al., 2019). In fact, recent studies support the notion that
GM reduction in schizophrenia varies with periods of active illness after the onset (Lepage et al., 2020), lifestyle factors (Moser
et al., 2018) and high doses of medication exposure (Ho,
Andreasen, Ziebell, Pierson, & Magnotta, 2011). Subgroups of
patients with markedly lower GM do not have a consistent pattern
of pronounced symptoms (Honnorat, Dong, Meisenzahl-Lechner,
Koutsouleris, & Davatzikos, 2019; Planchuelo-Gomez et al., 2020)
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or cognitive burden in schizophrenia (Pan et al., 2020;
Planchuelo-Gomez et al., 2020). In contrast, we noted that
patients with a shorter duration of illness, less severe positive
symptoms and better set-shifting ability had higher GM in the
covariance network comprised of fronto-temporal regions and
putamen. With a longer DUP (as well as age), the effect of higher
GM diminished in our sample, indicating that any resilience conferred by GM increase may not be sustained over longer periods
in untreated states. Given the cross-sectional nature of our data, it

Component
number
4

24

13

26

Loadings
directionality
HC > NN-FES

HC > NN-FES

NN-FES > HC

NN-FES > HC

L/R Volume
(cm3)

Brain region label

Brodmann area

Superior
Temporal Gyrus

13, 21, 22, 38,
41, 42

6.5/4.9

(−25, 10, −24)/
(27, 13, −23)

(−25.5, 12, −28.5)/
(27, 15, −27)

Insula

13, 22, 40, 41,
47

5.5/5.5

(−43, −16, 10)/
(45, −13, 10)

(−43.5, −16.5, 10.5)/
(45, −13.5, 10.5)

Inferior Frontal
Gyrus

9, 13, 44, 45, 47

3.7/4.2

(−37, 17, −18)/
(31, 16, −22)

(−37.5, 18, −21)/
(31.5, 18, −25.5)

Anterior
Cingulate

24, 25, 32, 33

1.6/1.6

(−1, 26, 25)/(1, 42,
−3)

(−15, 25.5, 28.5)/(15,
43.5, −15)

Precuneus

7, 19, 23, 31

6.8/7.3

(−9, −71, 34)/(30,
−73, 35)

(−9, −75, 33)/(30,
−76.5, 34.5)

Cuneus

7, 17, 18, 19, 23,
30, 31

4.6/4.2

(−10, −70, 31)/
(12, −67, 32)

(−10.5, −73.5, 30)/
(12, −70.5, 31.5)

Inferior Parietal
Lobule

7, 39, 40

1.6/1.6

(−36, −43, 45)/
(36, −45, 38)

(−36, −46.5, 46.5)/
(36, −48, 39)

Lingual Gyrus

17, 18

1.2/1.5

(0, −86, 3)/(1,
−83, 4)

(0, −88.5, −15)/(15,
−85.5, 0)

Superior Parietal
Lobule

7, 40

1.2/1.2

(−24, −66, 43)/
(30, −68, 43)

(−24, −70.5, 43.5)/
(30, −72, 43.5)

Superior
Temporal Gyrus

22, 39, 41, 42

1.1/0.0

(−43, −55, 29)/
(45, −60, 21)

(−43.5, −58.5, 28.5)/
(45, −63, 19.5)

Cerebellar Tonsil

NA

5.2/6.2

(−37, −54, −38)/
(36, −54, −38)

(−37.5, −54, −48)/
(36, −54, −48)

Inferior
Semi-Lunar
Lobule

*

1.2/1.5

(−34, −63, −36)/
(39, −62, −37)

(−34.5, −63, −46.5)/
(39, −61.5, −48)

Middle Temporal
Gyrus

20, 21, 22, 37,
39

2.6/1.2

(−56, −32, −6)/
(59, −32, −7)

(−57, −33, −9)/(60,
−33, −10.5)

Middle Frontal
Gyrus

20

2.3/2.8

(−36, 23, 21)/(34,
−34, 40)

(−36, 22.5, 24)/(34.5,
−37.5, 42)

Superior
Temporal Gyrus

13, 21, 22, 38,
39

1.9/0.6

(−45, −55, 29)/
(45, −46, 20)

(−45, −58.5, 28.5)/
(45, −48, 19.5)

Middle Frontal
Gyrus

6, 8, 9, 10, 46

1.0/1.1

(−36, 8, 38)/(34,
25, 28)

(−36, 6, 42)/(34.5,
24, 31.5)

Inferior Parietal
Lobule

40

0.3/1.8

(−53, −25, 25)/
(36, −34,40)

(−54, −27,25.5)/(36,
−37.5, 42)

Putamen

NA

0.1/0.4

(−28, 10, −6)/(30,
8, −8)

(−28.5, 10.5, −6)/
(30, 9, −9)

Talairach (x, y, z)

MNI (x, y, z)

F
value

p value (FDR
Corrected)

GMC Effect
sizea (partial eta
squared)

27.33

<0.001

0.039

12.30

0.004

0.018

12.70

0.004

0.018

7.91

0.028

0.012

7

Note: HC, healthy control; NN-FES, ﬁrst-episode neuroleptic-naïve patients with schizophreniform psychosis and schizophrenia; MNI, Montreal neurological institute; FDR, false discovery rate. >
a
Effect sizes were computed after extracting mean GMC from the spatial components from each subject; these were not calculated from loading coefficients.
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Table 2. Loading directionality and brain labels for the spatial components showing NN-FES /HC difference
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Fig. 2. Patterns of grey matter alterations in ﬁrst-episode neuroleptic-naïve patients with schizophreniform psychosis and schizophrenia. Abbreviations: GMC, grey
matter concentration; NN-FES, ﬁrst-episode neuroleptic-naïve patients with schizophreniform psychosis and schizophrenia; SPL, Superior Parietal Lobule; IPL,
Inferior Parietal Lobule; STG, Superior Temporal Gyrus; ACC, Anterior Cingulate Cortex; IFG, Inferior Frontal Gyrus; MTG, Middle Temporal Gyrus. Component 4
including insular, ACC, STG and IFG regions is shown in red; Component 24 including precuneus and cuneus, lingual gyrus, SPL, IPL and STG is shown in yellow;
Component 26 including MFG, MTG, IPL, STG and putamen is shown in blue; Component 13 including cerebellar Tonsil and inferior Semi-Lunar Lobule is shown in
purple.

Table 3. Differences in neurocognitive components between NN-FES and HC
CANTAB

NN-FES (n = 210)

HC (n = 253)

df

T value

p value

0.52 (0.74)

461

15.07

<0.00

Component 1

−0.63 (0.90)

Component 2

−0.26 (1.31)

0.22 (0.56)

461

5.22

<0.00

Component 3

−0.11 (1.37)

−0.09 (0.50)

461

2.07

0.04

Component 4

−0.22 (1.19)

0.18 (0.75)

461

4.43

<0.00

Note: NN-FES, ﬁrst-episode neuroleptic-naïve patients with schizophreniform psychosis and schizophrenia; HC, health control; CANTAB, Neurocognitive scores using the Cambridge
Neuropsychological Test Automated Battery. Cognitive scores contributing to each of the 4 components were numerically higher in healthy subjects than in patients. For ease of
interpretation, the factor loading signs are retained for components 1, 3 and 4, but reversed for component 2, with lower negative or higher positive loading representing better cognitive
ability. For the t test, absolute values of the t statistic are presented.

Table 4. Correlates of clinical and neurocognitive variables with SBM loadings in aggregate data
C4

C24

C13

C26

0.030 (0.611)

−0.035 (0.551)

0.027 (0.643)

0.152 (0.010)

Positive

−0.018 (0.755)

−0.115 (0.049)

−0.020 (0.728)

0.178 (0.002)

Negative

−0.066 (0.260)

−0.019 (0.749)

−0.018 (0.753)

−0.079 (0.179)

0.041 (0.482)

−0.077 (0.190)

0.017 (0.773)

0.028 (0.634)

Component 1

−0.098 (0.236)

0.137 (0.095)

−0.093 (0.261)

0.187 (0.022)

Component 2

−0.102 (0.214)

−0.033 (0.691)

0.140 (0.090)

0.220 (0.007)

Component 3

−0.060 (0.464)

−0.009 (0.910)

0.074 (0.370)

−0.079 (0.338)

Component 4

0.073 (0.375)

0.084 (0.310)

−0.118 (0.150)

0.060 (0.466)

DUP

Disorganisation
CANTAB

Note: R (uncorrected p value); False Discovery Rate-corrected for clinical features (p=0.04) or cognitive components (p=0.056) shown in bold; DUP, duration of untreated psychosis. Spearman
correlation analysis for DUP; Bivariate correlation analysis for PANSS; Partial correlation analysis for neurocognition factors with IQ as covariate.

is not possible to make causal inferences in this regard.
Longitudinal studies are required to clarify if higher GM is a
marker of resilience that contributes to early help-seeking despite
low levels of symptom burden.
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In VBM analysis, we found both groups to show a negative
correlation between GMC and age, with age-related lower
GMC being much more extensive in patients (online
Supplementary Fig. S6). This result was consistent with our

Psychological Medicine

previous finding of extensive and excessive age-related cortical
thickness loss in frontal, temporal, parietal, and cingulate gyri
in patients (Lin et al., 2019) and other previous studies reported
faster GM loss in cortical volume in first-episode patients with
schizophrenia (Arango et al., 2012; Cahn et al., 2002; Whitford
et al., 2006). The age-associated GMC reduction found in
neuroleptic-naïve first-episode schizophrenia provides evidence
for age-related accelerated brain changes independent of antipsychotic effects.
Our study has a number of strengths that could have contributed to our ability to observe both higher and lower GM in
schizophrenia. We recruited a somewhat homogenous, singleregional (Chengdu) sample whereby the variance due to referral
pathways and catchment demographics were minimal. Our continuous sampling of all referrals to the hospital eliminated the
bias of selecting only the most unwell subjects that are accepted
to treatment programmes. Furthermore, with a higher upper
bound for age of inclusion in our first-episode programme, we
achieved better sex balance in the sample (Bora, Fornito, Yücel,
& Pantelis, 2012) that captures the true prevalence pattern of
schizophrenia in the community (Huang et al., 2019). We were
able to scan participants before they were started on medications
and utilised a multivariate approach that included both cortical
and subcortical structures; this approach improved our sensitivity
to detect putative compensatory changes compared to mass univariate methods and approaches restricted to the cortical mantle.
We also had a number of limitations. We had only a single scan
from our sample and no long-term outcome records, thus we
were not able to relate the trajectories of illness to the brain structure at the onset. We also lacked information about lifestyle factors and other unconventional interventions that some of the
patients might have received before their presentation. Finally,
due to the challenging nature of the sampling procedure and
the long time required for this, we used two different scanners
in Chengdu. The diagnostic effects were stable across the scanners, but the increased GMC in the cerebellum was not seen in
the smaller of the two datasets; we urge caution in generalising
the results pertaining to this component. As in most other
imaging studies, we excluded patients incapable of consenting
and those who could not be scanned before instituting treatment
(e.g. high degree of hostility/aggression); this may affect the generalisation of results to patients with more adverse outcomes. We
focused on the GMC in the present study given its sensitivity in
picking up group-level differences when comparing patients
with schizophrenia and HC; covariance analysis using cortical
thickness (Palaniyappan, Al-Radaideh, Gowland, & Liddle,
2020), gyrification (Das et al., 2018) and surface area (Prasad
et al., 2021) are apt candidates for future studies to determine
the surface level cortical contribution to regions with relatively
higher GMC.
Conclusion
In summary, we provide evidence supporting relatively higher
GM occurring alongside a more extensive lower GM in early
stages of schizophrenia, in association with a favourable clinical
profile even before the onset of treatment. Structural cortical
reorganisation in response to early deficits may occur in schizophrenia well before the onset of illness and treatment exposure.
Such compensatory processes may indeed be contributing to
the unique profile of this illness (late developmental onset, relapsing and remitting course with partial recovery) when compared to
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neurodegenerative or early developmental disorders, as well as to
the heterogeneity of its clinical course.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291722000058
Acknowledgements. The authors would like to recognise, with great appreciation, all the study participants and their families who contributed to this
project.
Financial support. This work was partly supported by National Natural
Science Foundation of China (Key Project 81630030 to TL, 81920108018 to
TL and PCS, 82071524 to ML, 82001440 to XL); Post-Doctor Research
Project, West China Hospital, Sichuan University (2020HXBH042 to XL);
Special Foundation for Brain Research from Science and Technology
Program of Guangdong (2018|B030334001); 2021 Project for Hangzhou
Medical Disciplines of Excellence & Key Project for Hangzhou Medical
Disciplines; Science and Technology Project of Sichuan Province
(2021YJ0238 to ML);1.3.5 Project for Disciplines of Excellence, West China
Hospital, Sichuan University (ZY2016203, ZY2016103, ZYGD200004);
Introduction Project of Suzhou Clinical Expert Team (SZYJTD201715 to
XD and TL); Bucke Family Fund, The Chrysalis Foundation and The
Arcangelo Rea Family Foundation (LP); the Kilborn Fund for
Internalization, Schulich School of Medicine, University of Western Ontario
(to LP and TL); LP acknowledges salary support from the Tanna Schulich
Chair of Neuroscience and Mental Health.
Conflict of interest. LP reports personal fees from Janssen Canada, Otsuka
Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book
royalties from Oxford University Press; investigator-initiated educational
grants from Janssen Canada, Sunovion and Otsuka Canada outside the submitted work. All other authors report no relevant conflicts.

References
Annett, M. (1970). A classification of hand preference by association analysis.
British Journal of Psychology, 61(3), 303–321. https://doi.org/10.1111/j.20448295.1970.tb01248.x.
Arango, C., Rapado-Castro, M., Reig, S., Castro-Fornieles, J., Gonzalez-Pinto,
A., Otero, S., … Desco, M. (2012). Progressive brain changes in children
and adolescents with first-episode psychosis. Archives of General Psychiatry,
69(1), 16–26. https://doi.org/10.1001/archgenpsychiatry.2011.150.
Arnone, D., Cavanagh, J., Gerber, D., Lawrie, S. M., Ebmeier, K. P., &
McIntosh, A. M. (2009). Magnetic resonance imaging studies in bipolar disorder and schizophrenia: Meta-analysis. British Journal of Psychiatry, 195
(3), 194–201. https://doi.org/10.1192/bjp.bp.108.059717.
Ashburner, J. (2007). A fast diffeomorphic image registration algorithm.
Neuroimage, 38(1), 95–113. https://doi.org/10.1016/j.neuroimage.2007.07.007.
Bora, E., Fornito, A., Yücel, M., & Pantelis, C. (2012). The effects of gender on
grey matter abnormalities in major psychoses: A comparative voxelwise
meta-analysis of schizophrenia and bipolar disorder. Psychological
Medicine, 42(2), 295–307. https://doi.org/10.1017/s0033291711001450.
Cahn, W., Hulshoff Pol, H. E., Lems, E. B., van Haren, N. E., Schnack, H. G.,
van der Linden, J. A., … Kahn, R. S. (2002). Brain volume changes in firstepisode schizophrenia: A 1-year follow-up study. Archives of General
Psychiatry, 59(11), 1002–1010. https://doi.org/10.1001/archpsyc.59.11.1002.
Chan, R. C., Di, X., McAlonan, G. M., & Gong, Q. Y. (2011). Brain anatomical
abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: An activation likelihood estimation meta-analysis of illness progression. Schizophrenia Bulletin, 37(1), 177–188. https://doi.org/10.1093/
schbul/sbp073.
Chopra, S., Fornito, A., Francey, S., O’Donoghue, B., Cropley, V., Nelson, B.,
… McGorry, P. (2021). Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A
longitudinal, randomised, triple-blind, placebo-controlled MRI study.
Neuropsychopharmacology: Official Publication of the American College of
Neuropsychopharmacology, 46(8), 1494–1501. https://doi.org/10.1038/
s41386-021-00980-0.

10
Das, T., Borgwardt, S., Hauke, D., Harrisberger, F., Lang, U., Riecher-Rössler,
A., … Schmidt, A. (2018). Disorganized gyrification network properties
during the transition to psychosis. JAMA Psychiatry, 75(6), 613–622.
https://doi.org/10.1001/jamapsychiatry.2018.0391.
Feng, R., Womer, F. Y., Edmiston, E. K., Chen, Y., Wang, Y., Chang, M., …
Wang, F. (2020). Antipsychotic effects on cortical morphology in schizophrenia and bipolar disorders. Frontiers in Neuroscience, 14, 579139.
https://doi.org/10.3389/fnins.2020.579139.
First, M. B., Spitzer, R., Gibbon, M, & Williams, J. B. (1996). Structured clinical interview for DSM-IV axis I disorders – Non-patient edition (SCID-I/
NP), version 2.0. New York: New York State Psychiatric Institute,
Biometrics Research.
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1997). Structured
clinical interview for DSM-IV axis I disorders: SCID-I: Clinician version:
Administration booklet. Washington, DC: American Psychiatric Press.
Glahn, D. C., Laird, A. R., Ellison-Wright, I., Thelen, S. M., Robinson, J. L.,
Lancaster, J. L., … Fox, P. T. (2008). Meta-analysis of gray matter anomalies
in schizophrenia: Application of anatomic likelihood estimation and network analysis. Biological Psychiatry, 64(9), 774–781. https://doi.org/10.
1016/j.biopsych.2008.03.031.
Gong, Y. (1992). Wechsler adult intelligence scale-revised in China version.
Changsha, Hunan, China: Hunan Medical College.
Guo, S., Palaniyappan, L., Liddle, P. F., & Feng, J. (2016). Dynamic cerebral
reorganization in the pathophysiology of schizophrenia: A MRI-derived
cortical thickness study. Psychological Medicine, 46(10), 2201–2214.
https://doi.org/10.1017/S0033291716000994.
Gupta, C. N., Calhoun, V. D., Rachakonda, S., Chen, J., Patel, V., Liu, J., …
Turner, J. A. (2015). Patterns of gray matter abnormalities in schizophrenia
based on an international mega-analysis. Schizophrenia Bulletin, 41(5),
1133–1142. https://doi.org/10.1093/schbul/sbu177.
Himberg, J., Hyvarinen, A., & Esposito, F. (2004). Validating the independent
components of neuroimaging time series via clustering and visualization.
Neuroimage, 22(3), 1214–1222. https://doi.org/10.1016/j.neuroimage.2004.
03.027.
Ho, B. C., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011).
Long-term antipsychotic treatment and brain volumes: A longitudinal
study of first-episode schizophrenia. Archives of General Psychiatry, 68(2),
128–137. https://doi.org/10.1001/archgenpsychiatry.2010.199.
Honea, R., Crow, T. J., Passingham, D., & Mackay, C. E. (2005). Regional deficits in brain volume in schizophrenia: A meta-analysis of voxel-based
morphometry studies. American Journal of Psychiatry, 162(12), 2233–
2245. https://doi.org/10.1176/appi.ajp.162.12.2233.
Honnorat, N., Dong, A., Meisenzahl-Lechner, E., Koutsouleris, N., &
Davatzikos, C. (2019). Neuroanatomical heterogeneity of schizophrenia
revealed by semi-supervised machine learning methods. Schizophrenia
Research, 214, 43–50. https://doi.org/10.1016/j.schres.2017.12.008.
Huang, Y., Wang, Y., Wang, H., Liu, Z., Yu, X., Yan, J., … Wu, Y. (2019).
Prevalence of mental disorders in China: A cross-sectional epidemiological
study. The Lancet Psychiatry, 6(3), 211–224. https://doi.org/10.1016/S22150366(18)30511-X.
Kasparek, T., Marecek, R., Schwarz, D., Prikryl, R., Vanicek, J., Mikl, M., &
Ceskova, E. (2010). Source-based morphometry of gray matter volume in
men with first-episode schizophrenia. Human Brain Mapping, 31(2),
300–310. https://doi.org/10.1002/hbm.20865.
Kay, S. R., Flszbein, A., & Opfer, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–
276. https://doi.org/10.1093/schbul/13.2.261.
Lepage, M., Makowski, C., Bodnar, M., Chakravarty, M. M., Joober, R., &
Malla, A. K. (2020). Do unremitted psychotic symptoms have an effect
on the brain? A 2–year follow-up imaging study in first-episode psychosis.
Schizophrenia Bulletin Open, 1(1), sgaa039. https://doi.org/10.1093/schizbullopen/sgaa039.
Li, M., Li, X., Das, T. K., Deng, W., Li, Y., Zhao, L., … Li, T. (2019). Prognostic
utility of multivariate morphometry in schizophrenia. Frontiers in
Psychiatry, 10, 245. https://doi.org/10.3389/fpsyt.2019.00245.
Lieberman, J. A., Small, S. A., & Girgis, R. R. (2019). Early detection and preventive intervention in schizophrenia: From fantasy to reality. American

https://doi.org/10.1017/S0033291722000058 Published online by Cambridge University Press

Mingli Li et al.
Journal of Psychiatry, 176(10), 794–810. https://doi.org/10.1176/appi.ajp.
2019.19080865.
Liloia, D., Brasso, C., Cauda, F., Mancuso, L., Nani, A., Manuello, J., … Rocca,
P. (2021). Updating and characterizing neuroanatomical markers in highrisk subjects, recently diagnosed and chronic patients with schizophrenia:
A revised coordinate-based meta-analysis. Neuroscience and Biobehavioral
Reviews, 123, 83–103. https://doi.org/10.1016/j.neubiorev.2021.01.010.
Lin, Y., Li, M., Zhou, Y., Deng, W., Ma, X., Wang, Q., … Li, T. (2019).
Age-related reduction in cortical thickness in first-episode treatment-naive
patients with schizophrenia. Neuroscience Bulletin, 35(4), 688–696. https://
doi.org/10.1007/s12264-019-00348-x.
Liu, N., Xiao, Y., Zhang, W., Tang, B., Zeng, J., Hu, N., … Lui, S. (2020).
Characteristics of gray matter alterations in never-treated and treated
chronic schizophrenia patients. Translational Psychiatry, 10(1), 136.
https://doi.org/10.1038/s41398-020-0828-4.
Lv, J., Di Biase, M., Cash, R. F. H., Cocchi, L., Cropley, V. L., Klauser, P., …
Zalesky, A. (2021). Individual deviations from normative models of brain
structure in a large cross-sectional schizophrenia cohort. Molecular
Psychiatry, 26, 3512–3523. https://doi.org/10.1038/s41380-020-00882-5.
Mancuso, L., Fornito, A., Costa, T., Ficco, L., Liloia, D., Manuello, J., … Cauda,
F. (2020). A meta-analytic approach to mapping co-occurrent grey matter
volume increases and decreases in psychiatric disorders. Neuroimage, 222,
117220. https://doi.org/10.1016/j.neuroimage.2020.117220.
Moser, D. A., Doucet, G. E., Lee, W. H., Rasgon, A., Krinsky, H., Leibu, E., …
Frangou, S. (2018). Multivariate associations among behavioral, clinical,
and multimodal imaging phenotypes in patients with psychosis. JAMA
Psychiatry, 75(4), 386–395. https://doi.org/10.1001/jamapsychiatry.2017.
4741.
Palaniyappan, L. (2017). Progressive cortical reorganisation: A framework for
investigating structural changes in schizophrenia. Neuroscience and
Biobehavioral Reviews, 79, 1–13. https://doi.org/10.1016/j.neubiorev.2017.
04.028.
Palaniyappan, L. (2019). Inefficient neural system stabilization: A theory of
spontaneous resolutions and recurrent relapses in psychosis. Journal of
Psychiatry & Neuroscience, 44(6), 367–383. https://doi.org/10.1503/jpn.
180038.
Palaniyappan, L. (2021). The neuroscience of early intervention: Moving
beyond our appeals to fear. Australian and New Zealand Journal of
Psychiatry, 55(10), 942–943. https://doi.org/10.1177/0004867421998765.
Palaniyappan, L., Al-Radaideh, A., Gowland, P., & Liddle, P. (2020). Cortical
thickness and formal thought disorder in schizophrenia: An ultra-high-field
network-based morphometry study. Progress in Neuro-psychopharmacology
& Biological Psychiatry, 101, 109911. https://doi.org/10.1016/j.pnpbp.2020.
109911.
Palaniyappan, L., Balain, V., & Liddle, P. F. (2012). The neuroanatomy of psychotic diathesis: A meta-analytic review. Journal of Psychiatric Research, 46(10),
1249–1256. https://doi.org/10.1016/j.jpsychires.2012.06.007.
Palaniyappan, L., Mahmood, J., Balain, V., Mougin, O., Gowland, P. A., &
Liddle, P. F. (2015). Structural correlates of formal thought disorder in
schizophrenia: An ultra-high field multivariate morphometry study.
Schizophrenia Research, 168(1–2), 305–312. https://doi.org/10.1016/j.
schres.2015.07.022.
Pan, Y., Pu, W., Chen, X., Huang, X., Cai, Y., Tao, H., … Palaniyappan, L.
(2020). Morphological profiling of schizophrenia: Cluster analysis of
MRI-based cortical thickness data. Schizophrenia Bulletin, 46(3), 623–632.
https://doi.org/10.1093/schbul/sbz112.
Planchuelo-Gomez, A., Lubeiro, A., Nunez-Novo, P., Gomez-Pilar, J., de
Luis-Garcia, R., Del Valle, P., … Molina, V. (2020). Identificacion of
MRI-based psychosis subtypes: Replication and refinement. Progress in
Neuro-psychopharmacology & Biological Psychiatry, 100, 109907. https://
doi.org/10.1016/j.pnpbp.2020.109907.
Prasad, K., Rubin, J., Mitra, A., Lewis, M., Theis, N., Muldoon, B., … Cape, J.
(2021). Structural covariance networks in schizophrenia: A systematic
review Part II. Schizophrenia Research, 239, 176–191. https://doi.org/10.
1016/j.schres.2021.11.036.
Ren, W., Lui, S., Deng, W., Li, F., Li, M., Huang, X., … Gong, Q. (2013).
Anatomical and functional brain abnormalities in drug-naive first-episode

Psychological Medicine
schizophrenia. American Journal of Psychiatry, 170(11), 1308–1316. https://
doi.org/10.1176/appi.ajp.2013.12091148.
Seeley, W. W., Menon, V., Schatzberg, A. F., Keller, J., Glover, G. H., Kenna,
H., … Greicius, M. D. (2007). Dissociable intrinsic connectivity networks
for salience processing and executive control. Journal of Neuroscience, 27
(9), 2349–2356. https://doi.org/10.1523/JNEUROSCI.5587-06.2007.
Stip, E., Mancini-Marie, A., Letourneau, G., Fahim, C., Mensour, B., Crivello,
F., & Dollfus, S. (2009). Increased grey matter densities in schizophrenia
patients with negative symptoms after treatment with quetiapine: A voxelbased morphometry study. International Clinical Psychopharmacology, 24
(1), 34–41. https://doi.org/10.1097/YIC.0b013e32831daf6c.
Takahashi, T., & Suzuki, M. (2018). Brain morphologic changes in early stages
of psychosis: Implications for clinical application and early intervention.
Psychiatry and Clinical Neurosciences, 72(8), 556–571. https://doi.org/10.
1111/pcn.12670.
Uddin, L. Q., Yeo, B. T. T., & Spreng, R. N. (2019). Towards a universal taxonomy of macro-scale functional human brain networks. Brain Topography,
32(6), 926–942. https://doi.org/10.1007/s10548-019-00744-6.
van der Gaag, M., Hoffman, T., Remijsen, M., Hijman, R., de Haan, L., van
Meijel, B., … Cuijpers, A. (2006). The five-factor model of the positive
and negative syndrome scale II: A ten-fold cross-validation of a revised
model. Schizophrenia research, 85(1), 280–287. https://doi.org/10.1016/j.
schres.2006.03.021.
Vita, A., De Peri, L., Deste, G., Barlati, S., & Sacchetti, E. (2015). The effect of
antipsychotic treatment on cortical gray matter changes in schizophrenia:
Does the class matter? A meta-analysis and meta-regression of longitudinal
magnetic resonance imaging studies. Biological Psychiatry, 78(6), 403–412.
https://doi.org/10.1016/j.biopsych.2015.02.008.
Vita, A., De Peri, L., Deste, G., & Sacchetti, E. (2012). Progressive loss of cortical gray matter in schizophrenia: A meta-analysis and meta-regression of

https://doi.org/10.1017/S0033291722000058 Published online by Cambridge University Press

11
longitudinal MRI studies. Translational Psychiatry, 2, e190. https://doi.org/
10.1038/tp.2012.116.
Voineskos, A. N., Mulsant, B. H., Dickie, E. W., Neufeld, N. H., Rothschild, A.
J., Whyte, E. M., … Flint, A. J. (2020). Effects of antipsychotic medication
on brain structure in patients with major depressive disorder and psychotic
features: Neuroimaging findings in the context of a randomized placebocontrolled clinical trial. JAMA Psychiatry, 77(7), 674–683. https://doi.org/
10.1001/jamapsychiatry.2020.0036.
Whitford, T. J., Grieve, S. M., Farrow, T. F., Gomes, L., Brennan, J., Harris, A.
W., … Williams, L. M. (2006). Progressive grey matter atrophy over the first
2–3 years of illness in first-episode schizophrenia: A tensor-based morphometry study. Neuroimage, 32(2), 511–519. https://doi.org/10.1016/j.neuroimage.2006.03.041.
Xiao, Y., Lui, S., Deng, W., Yao, L., Zhang, W., Li, S., … Gong, Q. (2015).
Altered cortical thickness related to clinical severity but not the untreated
disease duration in schizophrenia. Schizophrenia Bulletin, 41(1), 201–210.
https://doi.org/10.1093/schbul/sbt177.
Xu, L., Groth, K. M., Pearlson, G., Schretlen, D. J., & Calhoun, V. D. (2009).
Source-based morphometry: The use of independent component analysis to
identify gray matter differences with application to schizophrenia. Human
Brain Mapping, 30(3), 711–724. https://doi.org/10.1002/hbm.20540.
Yue, Y., Kong, L., Wang, J., Li, C., Tan, L., Su, H., & Xu, Y. (2016). Regional
abnormality of grey matter in schizophrenia: Effect from the illness or treatment? PLoS One, 11(1), e0147204. https://doi.org/10.1371/journal.pone.
0147204.
Zhang, X., Zhang, Y., Liao, J., Jiang, S., Yan, J., Yue, W., … Yan, H. (2018).
Progressive grey matter volume changes in patients with schizophrenia
over 6 weeks of antipsychotic treatment and their relationship to clinical
improvement. Neuroscience Bulletin, 34(5), 816–826. https://doi.org/10.
1007/s12264-018-0234-6.

